G01N 2800/2864
Sleep disorders
G01N2800/2864 (Sleep disorders) appears on 36 US grants and 70 published applications in this corpus.
Search patents in G01N- Granted patents
- 36
- Published applications
- 70
- Assignees
- 41
- Inventors
- 116
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 2 |
| 2006 | 1 | 4 |
| 2007 | 0 | 1 |
| 2008 | 0 | 1 |
| 2009 | 1 | 0 |
| 2010 | 0 | 1 |
| 2011 | 1 | 3 |
| 2012 | 1 | 3 |
| 2013 | 2 | 5 |
| 2014 | 1 | 5 |
| 2015 | 2 | 3 |
| 2016 | 1 | 3 |
| 2017 | 6 | 5 |
| 2018 | 2 | 6 |
| 2019 | 2 | 5 |
| 2020 | 1 | 6 |
| 2021 | 3 | 4 |
| 2022 | 1 | 3 |
| 2023 | 4 | 2 |
| 2024 | 3 | 4 |
| 2025 | 2 | 2 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Identification of protein biomarkers for diagnosis and treatment for sleep apnea2 Jun 2026US 12,644,894 B1Dasman Diabetes Institute
- Identification of metabolites for diagnosis and treatment for sleep apnea19 Aug 2025US 12,390,156 B1Dasman Diabetes Institute
- Treatment of circadian rhythm disorders21 Jan 2025US 12,201,604 B2Vanda Pharmaceuticals Inc.
- Basal ganglia-on-chip for screening therapeutic agents for brain and nervous system diseases16 Apr 2024US 11,959,909 B2Sogang University Research Foundation
- Treatment of circadian rhythm disorders5 Mar 2024US 11,918,556 B2Vanda Pharmaceuticals Inc.
- Treatment of circadian rhythm disorders22 May 2025US 2025/0161259 A1Vanda Pharmaceuticals Inc.
- Methods and Compositions for Evaluating Biomarkers in Salivary Exosomes and Evaluating Cognitive Fatigue15 May 2025US 2025/0154592 A1The Regents of the University of California
- Peptide derivatives and related uses as orexin agonists31 Oct 2024US 2024/0360175 A1Centessa Pharmaceuticals (UK) Limited
- Treatment of circadian rhythm disorders20 Jun 2024US 2024/0197671 A1Vanda Pharmaceuticals Inc.
- Treatment of circadian rhythm disorders16 May 2024US 2024/0156775 A1Vanda Pharmaceuticals Inc.
Most cited
By later US patents
- Treatment of circadian rhythm disorders30US 8,785,492 B2Vanda Pharmaceuticals Inc. · 2014
- Treatment of circadian rhythm disorders19US 9,060,995 B2Vanda Pharmaceuticals Inc. · 2015
- Treatment of circadian rhythm disorders14US 9,549,913 B2Vanda Pharmaceuticals Inc. · 2017
- Treatment of circadian rhythm disorders14US 9,730,910 B2Vanda Pharmaceuticals Inc. · 2017
- Treatment of circadian rhythm disorders13US 9,539,234 B2Vanda Pharmaceuticals Inc. · 2017